Pharmaceuticals

Asthma Disease Market Projected to Grow Steadily to $33.11 Billion by 2030

April 6, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Valuation Is Forecasted For The Asthma Disease Market By 2030 Starting From Its 2026 Size?

The asthma disease market has experienced robust expansion in recent years. It is forecast to grow from $25.93 billion in 2025 to $27.29 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.2%. The expansion observed in the historic period is attributable to limited awareness of asthma management, reliance on rescue medications, lack of advanced biologics, insufficient homecare infrastructure, and growing urban pollution levels.

The asthma disease market is anticipated to experience consistent expansion over the upcoming period. This market is projected to reach $33.11 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.0%. The expansion during the forecast timeframe is attributable to several factors, including the emergence of new biologics and combined treatments, a rise in the use of controller medications, the broadening of specialty clinics and homecare provisions, enhanced patient awareness and educational initiatives, and the incorporation of digital health monitoring and smart inhaler systems. Key trends anticipated in this period encompass the escalating global prevalence of asthma, a greater uptake of inhalation therapies, an increase in biologics and targeted therapeutic options, the extended reach of homecare and specialty clinics, and an emphasis on personalized and precise medical strategies.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25701&type=smp

What Primary Drivers Are Shaping The Development Of The Asthma Disease Market?

The increasing prevalence of respiratory disorders is expected to drive the expansion of the asthma disease market moving forward. Respiratory disorders involve a range of conditions affecting the lungs and breathing, including chronic obstructive pulmonary disease (COPD), bronchitis, and asthma. The rising occurrence of these disorders is attributed to particulate matter and nitrogen oxides, which irritate and inflame the airways, leading to breathing difficulties and exacerbating existing conditions such as asthma. These diseases can cause inflammation and airway remodeling, which in turn initiate or worsen asthma symptoms. For instance, in December 2023, the National Library of Medicine, a US-based national library, reported that by 2050, chronic obstructive pulmonary disease (COPD) cases in low- and middle-income countries are projected to more than double those in high-income countries, with sub-Saharan Africa expected to see a 59% increase and lead globally in COPD prevalence and cases by 2040. Hence, the growing prevalence of respiratory disorders is propelling the growth of the asthma disease market.

Which Segment Categories Define The Asthma Disease Market?

The asthma disease market covered in this report is segmented –

1) By Treatment Type: Controller Medications, Rescue Medications, Biologics, Combination Therapy

2) By Cause Of Asthma: Allergic Asthma, Non-Allergic Asthma, Exercise-Induced Asthma, Occupational Asthma

3) By Severity: Mild Intermittent, Mild Persistent, Moderate Persistent, Severe Persistent

4) By Route Of Administration: Oral, Inhaled, Intravenous, Other Route Of Administration

5) By End-Users: Hospitals, Homecare, Specialty Clinics , Other End-Users

Subsegments:

1) By Controller Medications: Inhaled Corticosteroids (ICS), Long-Acting Beta-Agonists (LABA), Leukotriene Receptor Antagonists (LTRA), Long-Acting Muscarinic Antagonists (LAMA), Methylxanthines

2) By Rescue Medications: Short-Acting Beta-Agonists (SABA), Systemic Corticosteroids, Anticholinergics

3) By Biologics: Anti-IGE Therapy, Anti-IL-5 Therapy, Anti-IL-4/IL-13 Therapy, Anti-TSLP Therapy

4) By Combination Therapy: ICS Or LABA Combinations, ICS Or LABA Or LAMA Combinations, ICS Or LAMA Combinations

What Major Market Trends Are Driving Changes In The Asthma Disease Market?

Leading firms in the asthma disease market are increasingly concentrating on utilizing sophisticated technologies, such as integrated Bluetooth-enabled sensor inhalers, to boost medication compliance, facilitate real-time tracking of usage, and support individualized disease care. These inhalers, equipped with digital sensors, synchronize usage data to a smartphone application, assisting individuals with asthma by monitoring their medication intake, enhancing adherence through timely reminders, and offering insights that aid in improved symptom observation and control. A notable example is the launch in July 2023 of the GoResp Digihaler (budesonide and formoterol) by Teva Pharmaceutical Industries Limited, an Israel-based pharmaceutical firm, in the UK. This marked it as Europe’s inaugural fully integrated digital inhaler system for both asthma disease and chronic obstructive pulmonary disease. Produced in Ireland, this particular inhaler features embedded sensors that detect and record inspiratory flow and the quality of usage. It connects with a patient application that visualizes inhalation performance, categorizing it as good, fair, or low or no, and allows reports to be shared with healthcare professionals via email or a dedicated clinician dashboard. Furthermore, the application delivers medication reminders to assist patients in maintaining therapy consistency, while concurrently providing clinicians with enhanced understanding of individual technique and adherence behaviors, thereby facilitating more customized interventions.

Who Are The Top Companies Competing In The Asthma Disease Market?

Major companies operating in the asthma disease market are Pfizer Inc., Merck & Co. Inc., Novartis AG, Sanofi S.A., AstraZeneca PLC, GlaxoSmithKline plc, Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Chiesi Farmaceutici S.p.A., Cipla Limited

Read the full asthma disease market report here:

https://www.thebusinessresearchcompany.com/report/asthma-disease-global-market-report

How Does The Asthma Disease Market Perform Across Major Global Regions?

North America was the largest region in the asthma disease market in 2025. The regions covered in the asthma disease market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Asthma Disease Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=25701&type=smp

Browse Through More Reports Similar to the Global Asthma Disease Market 2026, By The Business Research Company

Asthma Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/asthma-drugs-global-market-report

Anti Asthmatics And Copd Drugs Market 2026

https://www.thebusinessresearchcompany.com/report/anti-asthmatics-and-copd-drugs-market

Anti Asthmatics And Copd Drugs Market 2026

https://www.thebusinessresearchcompany.com/report/anti-asthmatics-and-copd-drugs-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795